What is CellFE?
CellFE is at the forefront of revolutionizing cell therapy production through advanced microfluidic-based gene editing technology. Their proprietary Ryva Mechanoporation System is engineered to empower researchers and developers in the cell therapy sector, facilitating the creation of affordable and highly effective treatments. By tackling critical challenges in scalability and cost, CellFE is dedicated to improving access to life-saving therapies and supporting innovators in delivering superior treatments to patients globally.
How much funding has CellFE raised?
CellFE has raised a total of $22M across 1 funding round:
Series A
$22M
Series A (2023): $22M with participation from Cota Capital, Merck Ventures, and Dynamk Capital
Key Investors in CellFE
Cota Capital
Cota Capital is an investment firm that focuses on early-stage technology companies addressing innovative challenges in the enterprise sector. They combine financial investment with deep operational expertise and industry insights to empower founders in building transformative businesses.
Merck Ventures
M Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact the company's core business areas. M Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success.
Dynamk Capital
Dynamk Capital is a New York-based venture capital firm that specializes in investing in life science industrials, focusing on tools, technologies, and services essential for the discovery, development, and production of life-saving therapies. The firm aims to support innovative companies that are advancing the field of life sciences.
What's next for CellFE?
The recent major enterprise-level funding and strategic investment signal a pivotal growth phase for CellFE. This capital infusion is expected to accelerate the company's product development, expand its market reach, and further solidify its position in the competitive cell therapy manufacturing landscape. CellFE's focus on enhancing the efficiency and affordability of cell therapies positions it for substantial impact and continued innovation in the biopharmaceutical industry.
See full CellFE company page
